Effects on innate immunity of a therapeutic dendritic cell-based vaccine for HIV-1 infection

Viral Immunol. 2012 Feb;25(1):37-44. doi: 10.1089/vim.2011.0044. Epub 2012 Jan 10.


Changes in natural killer (NK) cells according to their phenotype and expression of certain regulatory receptors were analyzed in a double-blind, controlled study of antiretroviral therapy (ART)-untreated HIV-seropositive patients, who had been vaccinated with monocyte-derived dendritic cells pulsed with inactivated HIV-1 autologous virus. This work extends other recently published studies of the same group of HIV-1(+) vaccinated patients, which demonstrated that the viral load significantly decreases and correlates inversely with an increase in HIV-specific T-cell responses in vaccinated patients, but not in controls who received placebo. Our results indicate that this vaccine raises the level of the NK CD56(neg) cell subpopulation, while levels of the NK CD56(dim) and NK CD56(bright) cells expressing the inhibitory receptor CD85j/ILT-2 fell in vaccinated patients. Taken together, these results suggest that this vaccine might enhance innate immunity by amplifying the inflammatory and cytolytic capacity.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS Vaccines / administration & dosage*
  • AIDS Vaccines / immunology
  • AIDS Vaccines / therapeutic use
  • CD56 Antigen / genetics
  • CD56 Antigen / metabolism*
  • Dendritic Cells / immunology*
  • Dendritic Cells / virology*
  • Double-Blind Method
  • Female
  • Flow Cytometry
  • HIV Infections / immunology
  • HIV Infections / prevention & control*
  • HIV Infections / virology
  • HIV-1 / immunology*
  • Humans
  • Immunity, Innate
  • Immunization
  • Killer Cells, Natural / cytology
  • Killer Cells, Natural / immunology*
  • Male
  • Treatment Outcome


  • AIDS Vaccines
  • CD56 Antigen
  • NCAM1 protein, human